Logo image of ABSI

ABSCI CORP (ABSI) Stock Fundamental Analysis

NASDAQ:ABSI - Nasdaq - US00091E1091 - Common Stock - Currency: USD

2.78  -0.06 (-2.11%)

After market: 2.8 +0.02 (+0.72%)

Fundamental Rating

3

Taking everything into account, ABSI scores 3 out of 10 in our fundamental rating. ABSI was compared to 559 industry peers in the Biotechnology industry. The financial health of ABSI is average, but there are quite some concerns on its profitability. ABSI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ABSI had negative earnings in the past year.
ABSI had a negative operating cash flow in the past year.
In the past 5 years ABSI always reported negative net income.
ABSI had a negative operating cash flow in each of the past 5 years.
ABSI Yearly Net Income VS EBIT VS OCF VS FCFABSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

ABSI's Return On Assets of -46.24% is in line compared to the rest of the industry. ABSI outperforms 52.06% of its industry peers.
ABSI has a Return On Equity of -54.06%. This is in the better half of the industry: ABSI outperforms 63.69% of its industry peers.
Industry RankSector Rank
ROA -46.24%
ROE -54.06%
ROIC N/A
ROA(3y)-43.94%
ROA(5y)-42.38%
ROE(3y)-52.85%
ROE(5y)-52.12%
ROIC(3y)N/A
ROIC(5y)N/A
ABSI Yearly ROA, ROE, ROICABSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ABSI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABSI Yearly Profit, Operating, Gross MarginsABSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

ABSI does not have a ROIC to compare to the WACC, probably because it is not profitable.
ABSI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ABSI has more shares outstanding
Compared to 1 year ago, ABSI has an improved debt to assets ratio.
ABSI Yearly Shares OutstandingABSI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ABSI Yearly Total Debt VS Total AssetsABSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 2.33 indicates that ABSI is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of ABSI (2.33) is better than 71.38% of its industry peers.
ABSI has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, ABSI is in line with its industry, outperforming 44.72% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.33
ROIC/WACCN/A
WACC15.85%
ABSI Yearly LT Debt VS Equity VS FCFABSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

ABSI has a Current Ratio of 5.72. This indicates that ABSI is financially healthy and has no problem in meeting its short term obligations.
ABSI has a Current ratio (5.72) which is in line with its industry peers.
A Quick Ratio of 5.72 indicates that ABSI has no problem at all paying its short term obligations.
With a decent Quick ratio value of 5.72, ABSI is doing good in the industry, outperforming 60.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.72
Quick Ratio 5.72
ABSI Yearly Current Assets VS Current LiabilitesABSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 20.96% over the past year.
Looking at the last year, ABSI shows a decrease in Revenue. The Revenue has decreased by -9.93% in the last year.
The Revenue has been growing by 17.09% on average over the past years. This is quite good.
EPS 1Y (TTM)20.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.55%
Revenue 1Y (TTM)-9.93%
Revenue growth 3Y-1.75%
Revenue growth 5Y17.09%
Sales Q2Q%31.29%

3.2 Future

The Earnings Per Share is expected to grow by 5.65% on average over the next years.
Based on estimates for the next years, ABSI will show a very strong growth in Revenue. The Revenue will grow by 62.86% on average per year.
EPS Next Y5.36%
EPS Next 2Y10.18%
EPS Next 3Y11.42%
EPS Next 5Y5.65%
Revenue Next Year85.14%
Revenue Next 2Y127.57%
Revenue Next 3Y91.52%
Revenue Next 5Y62.86%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ABSI Yearly Revenue VS EstimatesABSI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M
ABSI Yearly EPS VS EstimatesABSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ABSI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABSI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABSI Price Earnings VS Forward Price EarningsABSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABSI Per share dataABSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.18%
EPS Next 3Y11.42%

More info and screens

0

5. Dividend

5.1 Amount

ABSI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABSCI CORP

NASDAQ:ABSI (6/13/2025, 8:00:00 PM)

After market: 2.8 +0.02 (+0.72%)

2.78

-0.06 (-2.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-12 2025-08-12/bmo
Inst Owners64.09%
Inst Owner Change16.34%
Ins Owners7.68%
Ins Owner Change1.18%
Market Cap354.62M
Analysts82.67
Price Target9.31 (234.89%)
Short Float %20.17%
Short Ratio7.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.87%
Min EPS beat(2)-2.74%
Max EPS beat(2)10.49%
EPS beat(4)1
Avg EPS beat(4)-4%
Min EPS beat(4)-13.12%
Max EPS beat(4)10.49%
EPS beat(8)1
Avg EPS beat(8)-12.76%
EPS beat(12)2
Avg EPS beat(12)-8.49%
EPS beat(16)2
Avg EPS beat(16)-23.45%
Revenue beat(2)0
Avg Revenue beat(2)-37.7%
Min Revenue beat(2)-63.32%
Max Revenue beat(2)-12.08%
Revenue beat(4)0
Avg Revenue beat(4)-28.74%
Min Revenue beat(4)-63.32%
Max Revenue beat(4)-4.87%
Revenue beat(8)1
Avg Revenue beat(8)-35.2%
Revenue beat(12)2
Avg Revenue beat(12)-34.42%
Revenue beat(16)2
Avg Revenue beat(16)-35.96%
PT rev (1m)0%
PT rev (3m)5.8%
EPS NQ rev (1m)5.52%
EPS NQ rev (3m)-4.76%
EPS NY rev (1m)3.05%
EPS NY rev (3m)-5.04%
Revenue NQ rev (1m)-5.52%
Revenue NQ rev (3m)-71.07%
Revenue NY rev (1m)-2.55%
Revenue NY rev (3m)-29.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 73.65
P/FCF N/A
P/OCF N/A
P/B 1.78
P/tB 2.29
EV/EBITDA N/A
EPS(TTM)-0.92
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0.04
BVpS1.56
TBVpS1.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.24%
ROE -54.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.94%
ROA(5y)-42.38%
ROE(3y)-52.85%
ROE(5y)-52.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.29%
Cap/Sales 8.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.72
Quick Ratio 5.72
Altman-Z 2.33
F-Score3
WACC15.85%
ROIC/WACCN/A
Cap/Depr(3y)44.41%
Cap/Depr(5y)179.67%
Cap/Sales(3y)101.78%
Cap/Sales(5y)229.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.55%
EPS Next Y5.36%
EPS Next 2Y10.18%
EPS Next 3Y11.42%
EPS Next 5Y5.65%
Revenue 1Y (TTM)-9.93%
Revenue growth 3Y-1.75%
Revenue growth 5Y17.09%
Sales Q2Q%31.29%
Revenue Next Year85.14%
Revenue Next 2Y127.57%
Revenue Next 3Y91.52%
Revenue Next 5Y62.86%
EBIT growth 1Y-19.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.01%
EBIT Next 3Y8.38%
EBIT Next 5YN/A
FCF growth 1Y14.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.9%
OCF growth 3YN/A
OCF growth 5YN/A